Wall Street edged higher in midday trading Thursday, given a slight boost by energy stocks after crude oil topped $60 a barrel.
IsoRay does a poor job selling radioactive 'seeds' for use in cancer radiation therapy but makes up for it by issuing a lot of promotional press releases.
Pharmaceuticals can be good investments. The companies are protected by patents for drugs they are developing.
Pharmaceutical stocks can be good investments. Here are some of the best pharmaceutical companies TheStreet Quant Ratings says you should consider looking at.
After four and a half months of follow-up, the sickle cell patient's blood contained 24% 'marked' beta globin, a measure of normally functioning hemoglobin, Bluebird announced Thursday.
Johnson & Johnson announced plans to file for federal approval of at least 10 potential blockbuster new drugs over the next four years. What does this mean for the stock?
Prima Biomed (PBMD) shares are rising sharply after the company announced the results of the trials for its ovarian cancer treatment.
Johnson & Johnson (JNJ) announced its Janssen Pharmaceutical segment will file for regulatory approval of at least ten new drugs by 2019.
Sarepta Therapeutics (SRPT) shares are up almost 50% after the company announced a positive pre-new drug approval meeting with the FDA.
TheStreet's Jim Cramer says Regeneron Pharmaceuticals' shares are headed even higher, and he comments on the huge rally in Sarepta Therapeutics' stock.
Allergan blazed a trail when its wrinkle-fighting treatment Botox opened up the facial aesthetics market. Now Kythera is attempting to follow that path with its double-chin drug Kybella.
Kythera has high expectations for the targeted launch of its FDA-approved double chin injection Kybella in the second half of 2015, said the company's CEO Keith Leonard.
Bluebird Bio and Intercept Pharma have reached separate agreements with regulators on the designs of key clinical trials for their respective blood disorder and fatty liver disease drugs.
Here are some of the best biotech companies TheStreet Quant Ratings says you should consider looking at.
The speculation of another hepatitis C-related acquisition took off Monday afternoon, sparked by a rumor that Gilead executives canceled a scheduled Tuesday presentation at a health care investor conference.
Select the service that is right for you!COMPARE ALL SERVICES
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV